Announcements
The Implementation Plan and the Capacity-building Action Plan for the Cartagena Protocol on Biosafety
Read the Implementation Plan and the Capacity-building Action Plan, adopted at CP-MOP 10.
Poll on Public Awareness, Education and Participation regarding LMOs
Results of the poll
Webinar “20 Years of the Safe Use of Biotechnology”
Recording of the webinar, held on 11 September 2023, to celebrate the 20th anniversary of the entry into force of the Cartagena Protocol on Biosafety.
Parties to the Cartagena Protocol
- 341 National Focal Points
- 402 Competent National Authority
- 16 Supplementary Protocol Competent Authority
- 1146 Biosafety Law, Regulation, Guidelines and Agreements
- 2777 Country's Decision or any other Communication
- 2665 Risk Assessment generated by a regulatory process
- 151 National Biosafety Website or Database
- 145 Fourth National Report on the Implementation of the Cartagena Protocol on Biosafety
- 160 Third National Report on the Implementation of the Cartagena Protocol on Biosafety
- 367 Biosafety Expert
- 168 Country Profile for Biosafety Clearing-House
National records
Recently published
BCH National Focal Point | Emergency Measures (Article 17) Contact Point
Black Nightshade with reduced pathogenesis-related protein 1S synthesis | Black nightshade, SOLNI | Black Nightshade with reduced pathogenesis-related protein 1S synthesis. | Black nightshade, SOLNI
Potato with altered growth and tuber quality | Potato, SOLTU
Poplar modified for increased glutathione content | Gray Poplar
CBD National Focal Point | Cartagena Protocol National Focal Point | Global Taxonomy Initiative National Focal Point
Black nightshade modified for reduced production of endogenous proteinase inhibitors | Black nightshade, SOLNI
Black nightshade modified for reduced production of endogenous prosystemin | Black nightshade, SOLNI
Reference records
Recently published
The objective of the multi-country project is to strengthen institutional, human and regulatory capacities and promote cooperative measures in the implementation of National Biosafety Frameworks for the safe transfer, handling and use of Living Modified Organisms (LMOs) in Asia. It has four components: (i) Multi-country collaboration and cooperation on Biosafety issues (ii) Facilitating the establishment, further development and effective implementation of biosafety systems at the national level (iii) Systems for information sharing, knowledge management, education and public awareness developed, and (iv) Project Monitoring and Evaluation.
KIPABiC is a non-profit organization, established on 23 November 2021 under Article 32 of the Civil Law of the Republic of Korea. KIPABiC promotes biosafety capacity building through multi-country cooperation with a focus on the Asian Region. It is supported by Korea Biosafety Clearing House (KBCH) and the Ministry of Trade Industry and Energy (MOTIE) of the Republic of Korea to sustain the initiatives under Asia Biosafety Family (erstwhile known as Asia BCH Family) and work with the United National Environment Programme (UNEP) as a project implementing partner for the Global Environment Facility (GEF) Multi-country Project (10991).
The organisation is active in the area of development of novel ornamental plant varieties using genetic modification methods. Research and trial activity involves molecular characterization of GM plants and biosafety related comparative experiments (transgenic vs. parental controls)
Max Planck Institute of Molecular Plant Physiology(MPIMP) | Changes in physiology and/or production (Yield), Resistance to antibiotics (Kanamycin)
Max Planck Institute of Molecular Plant Physiology(MPIMP) | Changes in quality and/or metabolite content, Resistance to antibiotics (Hygromycin)
Max Planck Institute of Molecular Plant Physiology(MPIMP) | Changes in physiology and/or production, Resistance to antibiotics (Kanamycin)
Max Planck Institute of Molecular Plant Physiology(MPIMP) | Resistance to antibiotics (Hygromycin), Tolerance to abiotic stress
Max Planck Institute of Molecular Plant Physiology(MPIMP) | Changes in physiology and/or production (Yield), Resistance to antibiotics (Kanamycin)